Curis to Present at the RBC Capital Markets Healthcare Conference

CAMBRIDGE, Mass.--Curis, Inc. , a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the Company will be presenting at the RBC Capital Markets Healthcare Conference at 8:00 a.m. EST on March 2, 2010, in New York City.

Dan Passeri, Curis’ President and Chief Executive Officer, will participate in a panel called “New Targets in Cancer Therapy” that will be hosted by RBC analyst Jason Kantor, Ph.D.

There will be a corresponding audio webcast of the panel discussion, which can be accessed by visiting:

http://www.wsw.com/webcast/rbc116/panel1

The panel will be archived shortly after the live event and available for 30 days following the conference. In addition, it will be available for 30 days on the Investor Relations section of the Curis website at www.curis.com.

About Curis, Inc.

Curis is a drug development company that is committed to leveraging its innovative signaling pathway drug technologies to seek to create new targeted small molecule drug candidates for cancer. Curis is building upon its previous experiences in targeting signaling pathways, including in the Hedgehog pathway, in its effort to develop proprietary targeted cancer programs. For more information, visit Curis' website at www.curis.com.